Antidepressants While Pregnant? Study Says ADHD, Autism Risk May Not Be What It Seems

Millions of pregnant women take antidepressants each year. For a long time, a quiet fear has followed those prescriptions. Could the medication raise a child’s risk of ADHD or autism? A sweeping new analysis of nearly 26 million pregnancies offers the most reassuring answer yet. Crucially, the drugs themselves may not be the main explanation.

Depression affects between 15 and 20 percent of pregnant women, making antidepressants among the most commonly prescribed medications during pregnancy. Some earlier studies suggested a link between prenatal antidepressant use and conditions like attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD), and those findings were enough to push some women off their medication entirely.

Published in Lancet Psychiatry, the analysis pooled data from 37 studies covering more than 648,000 antidepressant-exposed pregnancies and nearly 25 million unexposed ones. Researchers did find small statistical associations with ADHD and autism in broad pooled analyses. But once they factored in mothers’ mental health histories and shared family genetics, those associations shrank sharply or vanished.

Family Genetics, Not Antidepressants, May Explain the Pregnancy ADHD and Autism Link

Researchers attacked the confounding problem from several angles. When they compared children whose mothers took antidepressants during one pregnancy but not another, the ADHD link dropped to non-significant levels. Then came the most revealing test: fathers’ antidepressant use during a partner’s pregnancy also predicted higher ADHD and autism rates in children. A father’s pills cannot cross the placenta or affect fetal brain development. If paternal antidepressant use during pregnancy also tracks with child outcomes, that strongly suggests family genetics, parental mental health, or home environment may be helping drive the link.

Pre-conception data told the same story. Women who took antidepressants before getting pregnant, not during pregnancy at all, also showed elevated risk associations for both ADHD and autism in their children. A medication cannot affect a fetus that does not yet exist. That pattern points toward pre-existing maternal conditions as an important part of the explanation, rather than a simple drug effect during pregnancy.

Higher Doses of Antidepressants During Pregnancy Did Not Show a Clear Autism Risk Pattern

Available dose data did not show a clear difference in autism risk between high-dose and low-dose exposure, though dose information was limited across most studies. If the drug were genuinely driving developmental outcomes, higher doses would be expected to produce higher risk.

SSRIs, the most commonly prescribed class, showed elevated associations in broad analyses, as did non-SSRIs. But when comparisons were restricted to medicated versus unmedicated women with similar underlying mental health conditions, almost all of those drug-specific signals disappeared. Two exceptions stood out: amitriptyline and nortriptyline, older tricyclic antidepressants often used as second- or third-line options or for specific clinical reasons. Under tighter scrutiny, amitriptyline retained a statistically significant link to ADHD, while amitriptyline and nortriptyline together showed a combined association with autism. The authors flagged this as a potential safety signal, though women on those medications tend to have more severe or treatment-resistant depression, so the elevated risk may reflect illness severity rather than the drugs. No elevated risk turned up for intellectual disability, motor disorders, or speech and language disorders.

Stopping Antidepressants During Pregnancy Carries Its Own Serious Risks

Quitting antidepressants cold during pregnancy is not a neutral act, and the risks of doing so are well documented in the broader psychiatric literature. Research clearly shows it can sharply raise the risk of relapse, particularly in women with recurrent or severe depression. Untreated depression in pregnancy brings its own consequences: preterm birth, low birthweight, higher rates of postpartum depression, and behavioral and cognitive difficulties in children down the road. For women with moderate to severe depression, the authors conclude that continuing antidepressants is the right call, with the possible exception of amitriptyline and nortriptyline. For women with mild depression, talk therapy and similar approaches may be a reasonable alternative.

One of the more eye-opening findings involves fathers. Paternal antidepressant use also predicted higher ADHD and autism rates in children, which makes the maternal link look less like a simple medication effect. A father’s depression or anxiety, and the family stress that often comes with it, may shape a child’s development just as meaningfully as anything happening in the womb. Researchers described perinatal psychiatry as having evolved into “a field of three, involving mother, infant, and father.”

Across 37 studies and tens of millions of pregnancies, the evidence keeps pointing the same direction: the statistical link between antidepressants and ADHD or autism in children appears to be driven by the underlying conditions that lead women to take antidepressants in the first place, not by the medications themselves. When researchers stripped away those confounding factors, the associations either disappeared or shrank to the point of statistical insignificance. Pregnant women who need treatment should think very carefully about stopping antidepressants on their own because of neurodevelopmental fears that this analysis does not strongly support.

---

Disclaimer: This article is based on a published systematic review and meta-analysis and is intended for informational purposes only. It does not constitute medical advice. Decisions about medication use during pregnancy should always be made in consultation with a qualified healthcare provider.

---